Both in Pharmaceuticals
BridgeBio Pharma vs Alnylam Pharmaceuticals
Over the past year BBIO returned +19.4% and ALNY returned −63.2%; their daily moves had a correlation of 0.20.
BBIO +19.4% ALNY −63.2%Growth of $1, one year, split-adjusted
| Metric | BBIO | ALNY |
|---|---|---|
| Price | $74.03 | $159.89 |
| Market cap | $14.42B | $21.42B |
| Today | −1.29% | +1.20% |
| 1 month | +11.9% | −27.3% |
| 6 months | +7.6% | −46.9% |
| Year to date | −3.2% | −59.8% |
| 1 year | +18.2% | −64.9% |
| Revenue growth (YoY) | +192.6% | +16.7% |
| Gross margin | 94.2% | 75.2% |
| Net margin | −23.5% | 148.6% |
| P/E (TTM) | — | 7.9× |
| Price / sales | 15.3× | 4.3× |
| Net cash | -$938.6M | $2.57B |
| Dividend yield | — | — |
| Volatility (60d) | 32.4% | 72.9% |
| Short % of float | 12.5% | 4.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).